Showing results (191-200 of 237) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2023
Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian CancerStephanie L Wethington, Payal D Shah, Lainie Martin, et al.
Science Translational Medicine|September 4, 2015
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemiaDavid L Porter, Wei-Ting Hwang, Noelle V Frey, et al.
Transplantation and Cellular Therapy|July 19, 2022
Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell LymphomasPeter A Riedell, Wei-Ting Hwang, Loretta J Nastoupil, et al.
Iscience|July 18, 2024
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancerHaineng Xu, Sarah B Gitto, Gwo-Yaw Ho, et al.
JCO Precision Oncology|July 27, 2023
Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung CancerCharu Aggarwal, Melina E Marmarelis, Wei-Ting Hwang, et al.
The New England Journal of Medicine|March 7, 2014
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIVPablo Tebas, David Stein, Winson W Tang, et al.
Cell Reports. Medicine|October 8, 2021
CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer modelsHaineng Xu, Erin George, Yasuto Kinose, et al.
Gynecologic Oncology|October 8, 2021
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancerPayal D Shah, Stephanie L Wethington, Cheyenne Pagan, et al.
JCO Precision Oncology|August 8, 2022
Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic AdenocarcinomaWilliam J Chapin, Jacob E Till, Wei-Ting Hwang, et al.
Blood|May 12, 2016
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapyVijay G Bhoj, Dimitrios Arhontoulis, Gerald Wertheim, et al.
Pageof 24